All In Biotech

Drug Trial Radar · NCT07917910

A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of HT-101 Injection in Combination With HT-102 Injection in Participants With Chronic Hepatitis B (CHB) Virus Infection

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Oct 30, 2028

Study completion Sep 17, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II trial of HT-101 + HT-102 in CHB: (1) functional cure in treatment-naïve patients (vs placebo); (2) efficacy of sequential interferon in previously treated patients.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

  • HT-101 + HT-102Drug

    HT-101 given by subcutaneous injection.HT-102 given by subcutaneous injection.

  • HT-101 placebo + HT-102 placeboDrug

    HT-101 placebo + HT-102 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving functional cure at Week 24 of follow-up after discontinuation of all anti-hepatitis B medications.Time frame: Up to Week 72

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.